Program

www.virology-education.com
The 5th International Workshop on HIV Pediatrics is accredited by the European Accreditation Council for Continuing Medical Education (EACCME)
Acknowledgements

Financial support for the 5th International Workshop on HIV Pediatrics has been provided by the following companies:

Silver level Sponsor

![ViiV Healthcare](image)

Principal Supporters

![AbbVie](image)

![Bristol-Myers Squibb Company](image)

![Janssen](image)

Non-Commercial Supporters

*support doesn’t imply affiliation in any way*

![European Academy of Paediatric HIV](image)

![UNICEF](image)

Academic Supporters

![Columbia University in the City of New York](image)

![HIVNET](image)

![Erasmus MC Schon Specialistziektecenten](image)

![Universiteit Stellenbosch University](image)
Content

Programme Book

5th International Workshop on HIV Pediatrics

- Acknowledgement Workshop sponsors p. ii
- Content Index p. iii
- Organising Committee p. iv
- Scientific Committee p. v
- General Information p. vi
- Program p. vii
- Invited Speakers p. xi
- Disclosure Statements Organizing Committee p.xx

Abstract Book

Reviews in Antiviral Therapy & Infectious Diseases 2013_7

- Abstracts - Oral presentations p. 01
- Abstracts - Poster presentations p. 23
- Author Index p. 73

Organizing Secretariat

Biltstraat 106, 3572 BJ Utrecht, the Netherlands
Phone: +31 30 230 7140 Fax: +31 30 230 7148
Email: info@virology-education.com
www.virology-education.com
Organizing Committee

Elaine Abrams, MD
ICAP Mailman School of Public Health, Columbia University, New York, USA

Jintanat Ananworanich, MD, PhD
HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand

Charles Boucher, MD, PhD
Department of Virology Erasmus Medical Center, Erasmus University Rotterdam, The Netherlands, The Netherlands

Edmund Capparelli, PharmD
Pediatric Pharmacology and Drug Discovery, University of California San Diego, USA

Mark Cotton, FCPaed (SA), PhD
Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital (TCH), Stellenbosch University, South Africa

Carlo Giaquinto, MD
Department of Paediatric of Padova and Paediatric AIDS and Clinical Research Unit, Padova, Italy

Diana Gibb, MD, MRCP, MSc
Medical Research Council Clinical Trials Group, London, United Kingdom

Lynne Mofenson, MD
Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, USA
Scientific Committee

Ruth Bland, BSc, MBChB, DCH, MRCPCH, MD
University of KwaZulu-Natal, Natal, South Africa

David Burger, PharmD, PhD
University of Nijmegen, Nijmegen, The Netherlands

Tsungai Chipato, MBChB
University of Zimbabwe, Harare, Zimbabwe

Kulkanya Chokephaibulkit, MD
Siriraj Hospital / Mahidol University, Bangkok, Thailand

Ashraf HassenCoovadia, MBChB
Coronation Wom.& Child. Hosp., Johannesburg, South Africa

Anita De Rossi, PhD
AIDS Reference Centter, Padova, Italy

Marinella Della Negra, MD
Hospital Emilio Ribas, San Paolo, Brazil

Brian Eley, MD
Red Cross Children’s Hospital, Cape Town, South Africa

Susan Fiscus, PhD
Retrovirology Core Laboratory, North Carolina, USA

Patricia Flynn, MD
St. Jude Children’s Research Hospital, Memphis, USA

Mary Fowler, MD
Makarere University,Kampala, Uganda

Tessa Goetghebuer, MD
Hôpital St. Pierre, Bruxelles, Belgium

Ellen Gould Chadwick, MD
Northwestern University, Chicago, USA

Laura Guay, MD
Elizabeth Glaser Pediatric AIDS Foundation, Washington, USA

Shirin Heidari, PhD
International AIDS Society, Genève, Switzerland

Nick Hellmann, MD
Elizabeth Glaser Pediatric AIDS Foundation, USA

Chewe Luo, MD, PhD
UNICEF, New York, USA

Dorothy Mbori-Ngacha, MD
University of Nairobi, Nairobi, Kenya

Dhayendre Moodley, MSc, PhD
Nelson Mandela School of Medicine, Durban, South Africa

Sharon Nachman, MD
SUNY Health Science Center at Stony Brook, New York, USA

Paul Palumbo, MD
Dartmouth-Hitchcock Medical Center, Lebanon, USA

Jorge Pinto, MD, DSc
Universidade Federal de Minas Gerais, Minas Gerais, Brazil

Thanyawee Puthanakit, MD
Chulalongkorn University, Bangkok, Thailand

Gabriella Scarlatti, MD, PhD
Ospedale San Raffaele, Milano, Italy

Annette Sohn, MD
Treat Asia, Bangkok, Thailand

Lynda Stranix-Chibanda, MBChB, MMED
University of Zimbabwe, Harare, Zimbabwe

Graham Taylor, MD
Imperial College, London, United Kingdom

Claire Thorne, BA MSc PhD
UCL, Institute of Child Health , London, United Kingdom

Gareth Tudor Williams, MD
Imperial College, London, United Kingdom

Ung Vibol, MD
National Pediatric Hospital, Phnom Penh, Cambodia

Evgeny Voronin, MD, PhD
Russian Clinical AIDS Center, Russia

Andrew Wiznia, MD
Jacobi Medical Center/Family Based Services, Bronx, NY, USA
General Information

Accreditation
Virology Education is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 5th International Workshop on HIV Pediatrics is designated for a maximum of 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

Badge Policy
All registered delegates are provided with an identity badge. Please wear it at all times to ensure admission to the meeting.

Certificate of Attendance
Delegates who require a certificate of attendance should inform the Meeting Secretariat. The certificates can be picked up during coffee break on Saturday 29 June. Please sign the attendance list every day of the conference.

Conference Materials
Presentations will be posted on www.virology-education.com shortly after the workshop. The abstracts are published in Reviews in Antiviral Therapy & Infectious Diseases, Volume 2013_7.

Evaluation Form
Evaluation forms will be distributed on Friday 28 June during the PM coffee break and on Saturday 29 June during the PM coffee break. Please complete the evaluation forms and return the forms to conference desk.

Meeting Secretariat
The meeting secretariat is situated at the entrance of the meeting room. The conference organizers can be addressed for all questions concerning the logistics of the meeting.

Social Program
The workshop dinner is scheduled for Friday evening 28 June for those delegates who are pre-registered.

Speakers
Presenters are requested to submit their presentation as early as possible, preferably in the break prior to their session.

Poster Session
Posters will be displayed during the meeting in the Concourse area. All posters must be displayed during the whole workshop.
## Program - Friday 28 June

### Opening of the Workshop

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15AM</td>
<td>Opening Session</td>
<td>D. Persaud</td>
</tr>
<tr>
<td>08.15AM</td>
<td>Opening Lecture: Pathways towards HIV Cure for Infected Children and Youth</td>
<td>D. Persaud</td>
</tr>
<tr>
<td>08.45AM</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Session 1: Management of Pediatric HIV Infection (I)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15AM</td>
<td>Using lopinavir concentrations in hair to assess risk of virological failure among Asian adolescents</td>
<td>W. Prasitsuebsai</td>
</tr>
<tr>
<td>09.30AM</td>
<td>PRINCE1: Safety and efficacy of ATV powder and RTV liquid in HIV-1-infected ART-naïve and experienced infants and children 3 months to 6 years of age</td>
<td>S. Biguenet</td>
</tr>
<tr>
<td>09.45AM</td>
<td>Pharmacokinetics of abacavir and lamivudine once- versus twice-daily in HIV-infected Thai children</td>
<td>P. Punyahotra</td>
</tr>
</tbody>
</table>

**10.00AM** Coffee Break

### Session 2: Management of Pediatric HIV Infection (II)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30AM</td>
<td>Case 1: A child with swollen hands</td>
<td>L. Aurpibul</td>
</tr>
<tr>
<td>11.00AM</td>
<td>Case 2: A child with refractory Anemia</td>
<td>K. Razali</td>
</tr>
<tr>
<td>11.30AM</td>
<td>Case 3: A child with cross eye</td>
<td>N. Kurniati</td>
</tr>
<tr>
<td>12.00PM</td>
<td>A randomized study comparing low dose versus standard dose lopinavir/ritonavir among HIV-infected children with virological suppression</td>
<td>T. Puthanakit</td>
</tr>
<tr>
<td>12.15PM</td>
<td>Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens</td>
<td>L. Aurpibul</td>
</tr>
</tbody>
</table>

**12.30PM** LUNCH

**01.30PM** Poster Viewing

### Session 3: Adolescents and HIV (I)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.30PM</td>
<td>PRO - standpoint</td>
<td>S. Bakeera-Kitaka</td>
</tr>
<tr>
<td>02.45PM</td>
<td>CON - standpoint</td>
<td>A. Sohn</td>
</tr>
<tr>
<td>03.00PM</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**03.30PM** Coffee Break
### Session 4: Adolescents and HIV (II)

**Chairs:** Chewe Luo & Shirin Heidari

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>04.00PM</td>
<td>Sex, drugs and ART – coming of age with perinatal HIV</td>
<td>E. Abrams</td>
<td></td>
</tr>
<tr>
<td>04.30PM</td>
<td>Prevalence of Depression amongst HIV Infected Adolescents in Malawi</td>
<td>A.C. Mazenga</td>
<td>O_06</td>
</tr>
<tr>
<td>04.45PM</td>
<td>Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection: the ANRS-EP38-IMMIP study</td>
<td>F. Buseyne</td>
<td>O_07</td>
</tr>
<tr>
<td>05.00PM</td>
<td>Poor retention of HIV-positive adolescents and youth enrolled in care and on treatment in Kenya</td>
<td>E. Koech</td>
<td>O_08</td>
</tr>
</tbody>
</table>

**05.15PM** *End of Plenary session*

### Program - Saturday 29 June

**Chairs:** Elaine Abrams & Jintanat Ananworanich

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00AM</td>
<td>CIPHER - project</td>
<td>S. Heidari</td>
<td></td>
</tr>
<tr>
<td>08.05AM</td>
<td><strong>Young Investigator Award</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.15AM</td>
<td>Late Breaker: Mother-to-child transmission of HIV continues to decline in the UK and Ireland</td>
<td>C. Thorne</td>
<td>O_09</td>
</tr>
<tr>
<td>08.30AM</td>
<td>Late Breaker: Roll-out of Universal Antiretroviral Therapy for HIV Infected Pregnant and Breastfeeding Women (“Option B+) in Malawi: Factors Influencing Retention in Care</td>
<td>L. Tenthani</td>
<td>O_10</td>
</tr>
</tbody>
</table>

### Session 5: Round table discussion: WHO Guidelines Update

**Moderators:** Elaine Abrams & Jintanat Ananworanich

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45AM</td>
<td>Pediatric guidelines</td>
<td>T. Puthanakit</td>
<td></td>
</tr>
<tr>
<td>09.05AM</td>
<td>PMTCT guidelines</td>
<td>N. Shaffer</td>
<td></td>
</tr>
<tr>
<td>09.25AM</td>
<td>Panel discussion; implementation issues</td>
<td>Ying-Ru Lo</td>
<td></td>
</tr>
<tr>
<td>09.45AM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**10.00AM** *Coffee break*

### Session 6: Emerging Issues in PMTCT (I)

**Chairs:** Edmund Capparelli & Gareth Tudor-Williams

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30AM</td>
<td>Safety and pharmacovigilance issues with Option B+</td>
<td>R. J. Simonds</td>
<td></td>
</tr>
<tr>
<td>11.00AM</td>
<td>In Utero HAART Exposure Associated with Decreased Growth among HIV-Exposed Uninfected Breast Fed Infants in Botswana</td>
<td>K. Powis</td>
<td>O_11</td>
</tr>
<tr>
<td>11.15AM</td>
<td>WHO HIV Drug resistance surveillance in children less than 18 months old newly diagnosed with HIV: results from Swaziland and Zimbabwe</td>
<td>M. Penazzato</td>
<td>O_12A/B</td>
</tr>
<tr>
<td>11.35AM</td>
<td>Elimination of new paediatric HIV infections: assessment of maternal and paediatric antiretroviral coverage in priority countries</td>
<td>O. Adetokunbo</td>
<td>O_13</td>
</tr>
</tbody>
</table>
11.50AM Vaginal delivery as option for HIV infected women: decreasing late preterm delivery rates in a European cohort collaboration

12.05PM Discussion

12.15PM Lunch

01.00PM Poster Viewing

Session 7: Comprehensive Pediatric Care (I)

Chairs: Claire Thorne & Thanyawee Puthanakit

02.00PM Long-term complications of treatment in children

K. Chokephaibulkit

02.30PM Progressive liver disease in patients with vertically-acquired HIV/HCV co-infection in Spain

P. Rojo

02.45PM Thailand National Program for Early Infant HIV Diagnosis: Six-year Experience using Real-time DNA PCR on Dried Blood Spots

W. Sirirungsi

03.00PM Discussion

03.30PM Coffee break

Session 8: Comprehensive Pediatric Care (II)

Chairs: Helen McIlcron & Nicole Ngo-Giang Huong

04.00PM New diagnostics for TB in children

M. Cotton

04.30PM Determinants of retention and mortality among HIV-infected children at ICAP-supported care and treatment facilities in Mozambique (2004-2011)

C.A. Teasdale

04.45PM When to start ART in children aged 2-5 years? Causal modeling analysis of IeDEA Southern Africa

M. Schomaker

05.00PM Closure
5th International Workshop on HIV Pediatrics

Invited Speakers
Pathways towards HIV Cure for Infected Children and Youth

Deborah Persaud, MD
Johns Hopkins University, USA

Deborah Persaud, MD is an Associate Professor of Pediatrics and the Director of the Pediatric Infectious Diseases Fellowship program at Johns Hopkins University School of Medicine. She is a graduate of the New York University School of Medicine; trained in pediatrics at Babies Hospital/ Columbia Presbyterian Medical Center in New York, where she was chief resident.

Her training in Infectious diseases was at New York University School of Medicine where she was an Aaron Diamond Post Doctoral Research Fellow and a faculty member. She joined the Johns Hopkins’ faculty in 1997 following a visiting lectureship at the Moi University, Eldoret, Kenya. Since coming to Johns Hopkins, she has established a translational research program focused on viral reservoirs in HIV-infected children and youth as barriers to cure of HIV for which she has received the Doris Duke Clinician Scientist Award and the Elizabeth Glaser Pediatric AIDS Foundation Scientist Award.

Dr. Persaud has published seminal studies on latent HIV reservoirs in children, and their clinical implications for treatment of this population. More recently, she has conducted key studies on use of therapeutic HIV vaccines to target the latent HIV reservoir. Her research focus has also included development of molecular assays to facilitate monitoring of HIV drug resistance in resource-limited settings through use of dried blood spots.

She is the Scientific Chair of the HIV Cure committee for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group where she will play a key role in leading the charge of identifying ways to eliminate HIV reservoirs in children and youth.

Disclosure: no financial relationships to disclose

Difficult cases in treatment/management of HIV in children in Asia
A child with swollen hands

Linda Aurpibul, MD
Chiang Mai University, Thailand

Linda Aurpibul, MD qualified with a medical degree (MD.) from Mahidol University, Bangkok Thailand in 1995. After she completed her residency training program, she has worked as a pediatrician and general practitioner at a community hospital in northern Thailand where HIV was epidemic (without access to effective antiretroviral treatment at that time).

She has been working as a researcher at the Research Institute for Health Sciences (RIHES), Chiang Mai University, Chiang Mai Thailand since 2005, and has completed her MPH from the Johns Hopkins Bloomberg School of Public health in 2010. Her current appointment includes being a co-investigator in clinical researches under the International Maternal Pediatrics, and Adolescents Clinical Trial (IMPAACT) network, and also be a membership of the Primary Therapy Scientific Committee and Hepatitis Working Group, IMPAACT network. She has more than 20 peer review articles.

Areas of research interest: simplification of antiretroviral regimens for children in resource limited settings to harmonize with adult treatment, growing up with HIV and other adolescent issues, long term complication of HIV and antiretroviral treatment, HIV-HBV co-infected children, prevention of mother to child HIV transmission with focus on maternal health after delivery.

Disclosure: no financial relationships to disclose
Difficult cases in treatment/management of HIV in children in Asia
*A child with refractory Anemia*

Kamarul Razali, MD
Kuala Lumpur, Malaysia

---

Difficult cases in treatment/management of HIV in children in Asia
*A child with cross eye*

Nia Kurniati, MD
Cipto Mangunkusumo Hospital, Indonesia

*Nia Kurniati, MD* has qualification as MD from University of Indonesia, Jakarta in 1990 and completed her residency training program in the same University.

She was appointed as pediatrician in Allergy- Clinical Immunology Service when she develop HIV service for children in the hospital. She has joined Treat Asia Pediatric Network since 2005

She is doing clinical research in the area of long term follow up of HIV infected children, vaccination and prevention of mother to child HIV transmission.

Disclosure: no financial relationships to disclose
Debate: Adolescents with high risk behavior should be offered PrEP --- Pro standpoint

Sabrina Bakeera-Kitaka, MD
Makarere University, Uganda

Sabrina Bakeera-Kitaka, MD is currently a Senior Lecturer of Paediatrics and Adolescent Health Medicine at the Makerere University College of Health Sciences, in Kampala, Uganda. She received her medical degree in 1995 from Makerere University, and her masters of paediatrics and child health in 2002.

She then completed a fellowship in Paediatric Infectious Diseases in 2006. Her particular research area of interest is pediatric HIV with particular emphasis on HIV infected adolescents. Her overall goals are to improve the health and well being of children and adolescents affected by HIV by appropriate care and treatment.

Dr. Bakeera has been a PI, Co-PI, and key investigator on various studies specific to adolescents with HIV, and has published over 12 manuscripts in peer reviewed journals. Since 2003, she has taken on the responsibility of directing the adolescent programs at the Pediatric Infectious Diseases Clinic (PIDC), based at the Baylor-Uganda Clinical Center of Excellence, at Mulago National Referral Hospital. She has also participated in global consultative meetings, and provided technical support for developing guidelines specific to the betterment of adolescents living with HIV. As a result of these previous experiences, she is aware of the importance of looking at adolescents living with HIV as a unique and vulnerable population who need to be supported to maintain their health, and engage in positive prevention efforts.

Disclosure: no financial relationships to disclose

Debate: Adolescents with high risk behavior should be offered PrEP --- Con standpoint

Annette Sohn, MD
TREAT Asia/amfAR, Thailand

Annette Sohn, MD is the Director of TREAT Asia and a Vice President of amfAR – The Foundation for AIDS Research.

She is based in Bangkok, where she directs an HIV research program in collaboration with a network of over 60 adult and pediatric clinical sites across the Asia-Pacific that are part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) global consortium.

Her own research focuses on pediatric HIV treatment outcomes and drug resistance, and human papillomavirus in adolescents.

She trained in Pediatric Infectious Diseases at the University of California, San Francisco and remains an Assistant Clinical Professor in the Department of Pediatrics.

Disclosure: no financial relationships to disclose
Sex, drugs and ART - coming of age with perinatal HIV

Elaine Abrams, MD
ICAP, Mailman School of Public Health, New York, USA

Elaine Abrams, MD is a professor of epidemiology and pediatrics at Columbia University and the senior director for research at ICAP. At ICAP Dr Abrams leads a large and varied research portfolio that addresses critical scientific questions in HIV prevention, care and treatment. She is also responsible for the development and implementation of pediatric and perinatal prevention initiatives within ICAP supported programs across sixteen Sub Saharan African countries. Dr Abrams has been an active investigator in the field of maternal-infant HIV transmission and the natural history of HIV disease in infants, children and youth children since the recognition of the epidemic in the United States. She developed a comprehensive research and care program for women and children with HIV infection in Central Harlem, the Family Care Center; has been actively involved in the development of international, national and local guidelines and policies for care and treatment; has conducted multiple studies, clinical trials and implementation science studies in the area of maternal and child HIV. She is currently the chair of the HIV treatment scientific committee of the NIH funded IMPAACT clinical trials. She also co-chairs the maternal-child health committee of the World Health Organization 2013 HIV guidelines group.

Disclosure
no financial relationships to disclose

Roundtable discussion: WHO Guidelines Update
Pediatric Guidelines

Thanyawee Puthanakit, MD
Chulalongkorn University, Bangkok, Thailand

Thanyawee Puthanakit, MD is a pediatric infectious disease specialist at Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. She is a former trainee of the Johns Hopkins University Fogarty AIDS International Training and Research Program.

She started her clinical research in pediatric HIV/AIDS focusing on opportunistic infections and antiretroviral therapy in resource limited settings at Research Institute of Health Sciences, Chiang Mai University in 2002.

She joined the HIV-NAT,Thai Red Cross AIDS research center, Bangkok in 2006 to lead the pediatric randomized early versus deferred treatment initiation among HIV-infected children in Thailand and Cambodia (the PREDICT study). She has been a member of the WHO Pediatric Antiretroviral Treatment Guidelines Writing Committee since 2005.

Disclosure
no financial relationships to disclose
Roundtable discussion: WHO Guidelines Update
PMTCT Guidelines

Nathan Shaffer, MD
HIV Department, World Health Organization (WHO), Geneva

Nathan Shaffer, MD obtained his MD degree from Columbia College of Physicians and Surgeons in 1982, completed his internal medicine residency and board certification at Boston City Hospital in 1985 and a 2-year fellowship in epidemiology (EIS) at the US Centers for Disease Control and Prevention (CDC) in 1988. He has been working on the prevention of mother-to-child HIV transmission (PMTCT) in a variety of capacities for more than 20 years. Currently, he is the technical lead and senior advisor for PMTCT in the HIV Department, World Health Organization (WHO), Geneva. In the 4 years he has been at WHO, he facilitated the 2010 PMTCT ARV guidelines and the maternal-child health section of the new 2013 consolidated HIV guidelines (being launched at the Kuala Lumpur IAS conference) and has been supporting global efforts to scale-up and implement more effective PMTCT regimens and services and achieve the 2015 goals of the Global Plan (to eliminate new paediatric infections). Previously, at the CDC, he was the PI of the short-course AZT trial conducted in Thailand (published 1999), and then developed and led CDC’s technical support team on global PMTCT, as part of PEPFAR. He has a strong background and interest in technical issues, operational research and programme support and implementation.

Disclosure
no financial relationships to disclose

Roundtable discussion: WHO Guidelines Update
Implementation issues

Ying-Ru Lo, MD, DTM&H
World Health Organization (WHO), Regional Office for the Western Pacific, Philippines

Ying-Ru Lo, MD, DTM&H has nearly 30 years of experience in HIV clinical management and public health. She successively worked as Infectious Diseases and Tropical Medicine Specialist in Hamburg, Germany, for WHO in Asia (Bangkok, Thailand and South East Regional Office, New Delhi, India), 2002-2007, then as WHO Global Coordinator for HIV Prevention in Geneva, 2007-2012. She recently moved back to Asia as WHO Regional Team Leader, HIV and STI (Western Pacific Regional Office, Manila, Philippines). She leads teams of highly specialized professionals to provide authoritative direction and specialized expertise and successfully contribute to the formulation of national and international HIV and STI strategies, assessments and progress analysis.

Her major interest lies in translating research to program implementation and studying the prevention benefit of antiretrovirals in the Asian epidemic context. She has coordinated the development of Guidelines on Couples HIV testing and Counseling (2012) including the first formal recommendations on treatment as prevention (TasP), reviewed the scientific evidence of TasP among men who have sex with men, and contributed to the development of a metrics framework.

She represents WHO in the HIV Clinical Trials Unit (CTU) Scientific Advisory Board of CAPRISA in South Africa and the current China CTU application.

Disclosure
no financial relationships to disclose
Safety and pharmacovigilance issues with Option B+

Robert Simonds, MD
Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)

Robert Simonds, MD is the Vice President of Program Innovation and Policy at the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), where he oversees the development and execution of new technologies and innovative approaches to optimize program effectiveness directed at the elimination of pediatric AIDS. Prior to joining EGPAF in 2010, he spent 20 years as a medical epidemiologist at the US Centers for Disease Control and Prevention (CDC) in its domestic and global AIDS programs, with a special focus on HIV prevention, care, and treatment of children. From 1998-2001, he worked in The HIV/AIDS Collaboration in Thailand, where he oversaw CDC’s technical assistance to the Royal Thai Government in the implementation of a national program to prevent mother-to-child HIV transmission. From 2001-2010, Dr. Simonds worked in CDC’s Global AIDS Program (GAP), including serving from 2004-2010 as Deputy Director, working with the Director to manage and supervise all activities of GAP. He worked on The President’s Emergency Plan for AIDS Relief (PEPFAR) from its inception in 2003, including serving as a PEPFAR Deputy Principal.

Disclosure no financial relationships to disclose

Long-term Complications of Treatment in Children

Kulkanya Chokephaibulkit, MD
Mahidol University, Thailand

Kulkanya Chokephaibulkit, MD graduated from Faculty of Medicine Siriraj Hospital, Mahidol University in Bangkok in 1985. She obtained Pediatric Infectious Disease fellowship training at Cedars-Sinai Medical Center in Los Angeles in 1992-1993, and served as Chief Resident at the University of Tennessee at Knoxville in 1993-1994. She has been Thai and American board certified in Pediatrics and American board certified in Pediatric Infectious Diseases. Currently, she is a Professor of Pediatrics and Chief of Infectious Diseases Division, Department of Pediatrics. Her current duties involve teaching, research, and direct patient care. She also serves as a member of the Executive Board of the Pediatric Infectious Diseases Society of Thailand, the National Board for Immunization of the Ministry of Public Health, and the Advisory Board of the National Security Health Office (NHSO) for HIV/AIDS. She has been a consultant of the Thai Ministry of Public Health on the issues of pediatric and adolescent HIV and PMTCT. She led the development of disclosure program which is widely implemented in Thailand and neighboring countries. Another prominent work is the comprehensive program for HIV-infected adolescents to promote knowledge and life-skill. Her research programs involve pediatric and adolescent HIV/AIDS, dengue, tuberculosis, and vaccine clinical trials.

Disclosure no financial relationships to disclose
New Diagnostics for TB in Children

Mark Cotton, FCPaed (SA), PhD
Stellenbosch University, South Africa

Mark Cotton, FCPaed, PhD is Head of Division of Paediatric Infectious Diseases and Director of the Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at Tygerberg Children’s Hospital (TCH), Faculty of Health Sciences, Stellenbosch University. He completed a 3 year fellowship in pediatric infectious diseases at University of Colorado-Denver, and also conducted laboratory-based research on apoptosis in pediatric HIV under the supervision of Dr Terri Finkel at the National Jewish Center for Respiratory Diseases and Immunology. On return to Tygerberg Academic Hospital, he completed a PhD on the role of apoptosis in pediatric HIV infection. He has been conducting a number of multicenter trials focusing on TB and HIV in children. He is a member of WHO technical task teams on HIV staging, ART and guidelines for Tuberculosis in children since 2004. He is a Specialist in Pediatric Infectious Diseases with extensive experience in managing HIV-infected children. He has been co-PI and investigator in a number of randomized clinical trials in children, both studies ART strategy and isoniazid prophylaxis and also ARV pharmacokinetics in HIV-infected children. The majority of studies are funded through the International Maternal Pediatric Adolescent AIDS Clinical Trial Group (IMPAACT). He is also the director of the Children’s Infectious Diseases Clinical Research Unit (KID-CTU) (clinical trial unit).

Disclosure no financial relationships to disclose
**Disclosure statements member of the Organizing Committee**

In order to ensure independence and objectivity of the workshop and to meet with the regulations of CME issuing agencies, it is required that faculty members, abstract presenters and invited speakers disclose relationships with a commercial interest if both the relationship is financial and occurred within the past 12 months and the individual has the opportunity to affect the content of CME about the products or services of that commercial interest.

This policy pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic.

Disclosure statements of the abstract presenters are included in the abstract. Potential Conflicts of Interest of the invited speakers are listed together with their biography.

<table>
<thead>
<tr>
<th>Name</th>
<th>Financial relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elaine Abrams, MD</td>
<td>No financial relationships to disclose</td>
</tr>
<tr>
<td>Jintanat Ananworanich, MD, PhD</td>
<td>Financial relationship with ViIV Healthcare</td>
</tr>
<tr>
<td>Charles Boucher, MD, PhD</td>
<td>Financial relationships with Abbott, Merck, Roche and ViIV Healthcare</td>
</tr>
<tr>
<td>Edmund Capparelli, PharmD</td>
<td>Financial relationships with Trius Pharmaceuticals, Cerexa Pharmaceuticals and Far-Manguinhos</td>
</tr>
<tr>
<td>Mark Cotton, FCPAed, PhD</td>
<td>No financial relationships to disclose</td>
</tr>
<tr>
<td>Carlo Giaquinto, MD</td>
<td>No financial relationships to disclose</td>
</tr>
<tr>
<td>Diana Gibb, MD, MRCP, MSc</td>
<td>No financial relationships to disclose</td>
</tr>
<tr>
<td>Lynne Mofenson, MD</td>
<td>No financial relationships to disclose</td>
</tr>
</tbody>
</table>
Program